Antibiotic Resistance

The discovery of antibiotics ranks among the greatest triumphs of modern medicine. Before penicillin came into widespread use in the 1940s, a scratch from a rose thorn or a routine childbirth could turn lethal, and surgeons operated in the shadow of infections they were powerless to stop. Within a generation, diseases that had culled humanity for millennia became, in wealthy countries at least, minor inconveniences dispatched by a course of pills. Yet the very success of these drugs sowed the seeds of a slower-moving crisis. Bacteria reproduce with staggering speed, and every population harbours rare individuals whose genes happen to render them impervious to a given drug. Expose that population to the antibiotic, and the vulnerable perish while the resistant survive and multiply. Alexander Fleming himself, accepting his Nobel Prize in 1945, warned with remarkable foresight that the careless use of penicillin would breed resistant microbes, a caution the world was slow to heed. This is natural selection compressed into days, evolution unfolding not over geological ages but on the timescale of a hospital ward, and it was, in retrospect, entirely predictable.

What has turned an inevitable biological process into a global emergency is the sheer scale of human misuse. Antibiotics are routinely prescribed for viral illnesses such as colds and influenza, against which they are utterly useless, because patients demand them and harried doctors find it easier to comply. Even greater quantities are consumed not by people but by livestock: on industrial farms, healthy animals are fed a steady diet of antibiotics to accelerate growth and to forestall the diseases that flourish in cramped conditions. Each unnecessary dose, whether swallowed by a patient or a pig, rewards resistant bacteria and hastens their spread. Resistance genes, moreover, are not confined within single species; bacteria can swap fragments of DNA directly, so that a gene conferring immunity in a harmless gut microbe may migrate into a dangerous pathogen. The result is a rising tide of superbugs that shrug off one drug after another.

The consequences are already grim and worsening. Infections that were once trivial to cure now claim well over a million lives worldwide each year, and some strains of tuberculosis, gonorrhoea, and hospital-acquired bacteria resist nearly every antibiotic in the pharmacy. In a handful of chilling cases, physicians have already encountered infections against which no available drug works at all. Physicians increasingly fall back on drugs of last resort, older and more toxic compounds shelved decades ago, and even these are beginning to fail. The danger extends far beyond the infections themselves. Much of modern medicine quietly depends on the assumption that bacterial infection can be controlled: organ transplants, cancer chemotherapy, joint replacements, and intensive care for premature infants all leave patients acutely vulnerable to microbes. Should antibiotics cease to work reliably, these routine miracles would become perilous gambles, and hospitals could revert to being places where the sick go as much to acquire fatal infections as to be cured of them.

Confronting the threat is maddeningly difficult, in part because the market offers little incentive to solve it. Developing a new antibiotic costs a fortune and takes many years, yet a successful drug would, sensibly, be held in reserve and used as sparingly as possible to preserve its potency. A medicine that is deliberately kept on the shelf generates scant profit, so pharmaceutical companies have largely abandoned the field in favour of drugs for chronic conditions that patients take for years. The pipeline of genuinely novel antibiotics has consequently dwindled to a trickle at the very moment it is most needed. Meanwhile the bacteria evolve relentlessly, indifferent to boardroom calculations. Economists describe the predicament as a classic tragedy of the commons: antibiotics are a shared resource that everyone has an incentive to exploit and no one has a sufficient incentive to protect.

Averting catastrophe will require action on many fronts at once. Doctors and patients must learn to use existing antibiotics more judiciously; farmers must curb the reckless dosing of healthy livestock; and governments may need to underwrite antibiotic research with public money or guaranteed rewards, since the market alone will not. Improved sanitation, vaccination, and rapid diagnostic tests that distinguish bacterial from viral infection can all reduce the pressure that drives resistance. None of these measures is glamorous, and none offers a permanent victory, for resistance can be slowed but never abolished. The wealthy world, moreover, cannot solve the problem alone, since resistant bacteria travel effortlessly across borders in the bodies of travellers and the flesh of traded animals, making the crisis an inescapably global one. The realistic goal is not to defeat evolution but to stay a step ahead of it, husbanding our dwindling arsenal while science labours to replenish it. The age of easy cures, humanity is belatedly learning, was never guaranteed to last.